... polymorphism andlungcancer risk. Cancer Epi-demiol Biomarkers Prev 2001; 10: 911-2. 26. Chen S, Tang D, Xue K, et al. DNA repair gene XRCC1 and XPD polymorphisms and risk of lungcancer in ... gene XPD and risk of primary lung cancer. Lung Cancer 2002; 36: 15-6. 28. Harms C, Salama SA, Sierra-Torres CH, et al. Polymorphisms in DNA repair genes, chromosome aberrations, andlung cancer. ... repair gene XPD poly-morphism andlungcancer risk: a meta-analysis. LungCancer 2004; 46: 1-10. 51. Benhamou S, Sarasin A. ERCC2 /XPD gene polymorphisms and lung cancer: a HuGE review. Am J...
... Affected by LungCancer The following therapies are used to treat bones affected by lung cancer: ã Lungcancer treatment. The prompt initiation of appropriate therapy for lungcancer is ... The Bone andCancer Foundation The mission of The Bone andCancer Foundation is to: ã Provide information to cancer patients and family member on the causes and current ... information can be found in the Bone andCancer Foundation publication “Osteonecrosis of the Jaw – Information for Cancer Patients” available online at www.boneandcancerfoundation.org or by calling...
... NICE Guideline – lungcancer 4 Introduction In England and Wales, nearly 29,000 deaths were attributed to lungcancer in 2002. Lungcancer is the most common cause of cancer death for men, ... account for 60% of lungcancer cases. In women, lungcancer is the second most common cause of cancer death after breast cancer. Survival rates for lungcancer are very poor. In England, for patients ... needed into the symptoms and signs associated with early- and late-stage lungcancerand the factors associated with delay in presentation. For patients diagnosed with lung cancer, analysis should...
... betweensmoking and different histological types of lungcancer 4-184-11 Lungcancer deaths attributable to tobacco smoking in certain countries 4-245-1 Epidemiologic studies on ETS andlungcancer ... and active smokers 3-434-1 Main characteristics of major cohort studies on therelationship between smoking andcancer 4-64-2 Lungcancer mortality ratios prospective studies 4-84-3 Lungcancer ... risks of lungcancer in some large cohort studies amongmen smoking cigarettes and other types of tobacco 4-154-8 Age-adjusted lungcancer mortality ratios for males and females,by tar and nicotine...
... in every areaexcept Iceland and ranged from 8 or more in Slovenia, Spain,France and Italy, to more than 14 in the Netherlands.The proportion of lungand bronchus cancers that did not have ... smoking and lungcancer varies by cell type, with the odds ratios historicallylargest for squamous and small cell carcinomas and somewhatFIGURE 2 –CONTINUED.297INTERNATIONAL LUNGCANCER TRENDS ... Isere,Somme and Tarn); for Spain from Navarra and Tarragona; and forSwitzerland (1983 on) from Basel, Geneva and Zurich. We usedthe data from Varese for Italy, from Eindhoven for the Nether-lands and...
... exhaust andlung cancer. Our purpose was to evaluate the relationship between quantitative estimates of exposure to diesel exhaust andlungcancer mortality after adjustment for smoking and other ... exposure–response relationship for diesel exhaust andlungcancer with adjustment for potential confounding from cigarette smoking and other risk factors for lung cancer. We conducted a cohort mortality ... exhaust andlungcancer mortality after adjustment for cigarette smoking and other potential confounding factors that were unavailable in the cohort study.Materials and MethodsCohort Design and...
... promoter and, subsequently, the relative expression of p73 iso-forms in lungcancer by using lungcancer cell lines and tumour samples. Sp1 was found to activate thetranscription of TAp73c in lungcancer ... (CALU6), in the squamous lung cancer cell lines (HTB59, HTB58, and SKMES1), inthe adenocarcinoma cell lines (CALU3, CRL5935,A549, and SKLU1), and in the large cell lung cancer cell line (CORL23). ... 19) of squamous cell lungcancer samples, and in50% (13⁄ 26) of total lungcancer samples. Figure 4Cshows TAp73 and Sp1 levels in representative squa-mous cell carcinoma and adenocarcinoma samples(Fig....
... blotting and dot blotting of the analytical density gradients(Figs 5 and 6). Fraction 1 represents the top of thegradient, and fraction 11 is the bottom of the gradient.Fractions 3 and 4 and fractions ... in fraction 4 (70%) and in fraction 6(30%). Immunodetection of MRP1 in the absence (B) and in thepresence (C) of treatment with MbCD. S and R stand for GLC4(sensitive) and GLC4 ⁄ ADR (resistant) ... (2001) Kinetics ofglutathione and daunorubicin efflux from multidrugresistance protein overexpressing small-cell lung cancer cells. Eur J Pharmacol 421, 1–9.56 Fernandez-Checa JC & Kaplowitz...
... was ≥ 85% in 59% and 68%, and < 50% inonly 5% and 8% of arm A and B patients, respectively.Gemcitabine RDI was ≥ 85% in 33% and 74%, and < 50%in 23% and 0% of arm A and B patients, respectively. ... Tonato M: Gemcitabine and cisplatin versus mito-mycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin ... J Cancer 2001, 94:153-156.2. Non-small Cell LungCancer Collaborative Group: Chemotherapyin non small cell lung cancer: a meta-analysis using updateddata on individual patients from 52 randomized...
... between small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) [1]. The molecular pathogenesis of lung cancer, as far as it has been deciphered, consists of genetic and epigenetic alterations, ... cell lung cancerand non-small cell lung cancer. J Carcinog 2006, 20:4.28. Kargi A, Gurel D, Tuna B: The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung ... chromosome condensation protein G wasTable 1: Classification of significantly deregulated lungcancer genes in comparison to normal lung tissue with respect to cancer subtype and biological functions.functional...
... clinical and laboratory data, data analysis and interpretation, and drafted the manuscript. PP and LG participated inacquiring clinical and laboratory data, data analysis and data interpretation and ... methylation patterns in lung cancer. Seminarsin Cancer Biology 2009, 19(3):181-187.7. Costello JF, Fruhwald MC, Smiraglia DJ: Aberrant CpG-island methylationhas non-random and tumour-type-specific ... diagnosis, prog-nosis and/ or detection of metastatic pot ential of tumors,including lung cancer. As the number of genes methy-lated in cancer is large and increasing, sensitive and robust multiplexed...
... small cell lungcancer (NSCLC) specimens and to correlate its mRNA or protein expression with patients’ clinico-pathological features.Materials and methods: Quantitative real-time PCR and immunohistochemistry ... information and final writing of the manuscript. VM, SS, PC and EB participated in acquiringclinical and laboratory data, data analysis and data interpretation and draftedthe manuscript. MP and GVS ... in cancer pathology. Pathology 2007, 39:305-318.20. Bremnes RM, Veve R, Hirsch FR, Franklin WA: The E-cadherin cell-celladhesion complex andlungcancer invasion, metastasis, and prognosis.Lung...
... Cathepsins K, L, and S activity profiles in human lung cancer. A) Different stages (I, II, and III) of lungcancerand normal lung tissues were obtained and prepared as described. 10 μg of protein were ... Cathepsins K, L, and S inHuman Breast, Lung, and Cervical Cancer Binbin Chen and Manu O Platt*AbstractBackground: Cathepsins K, L, and S are cysteine proteases upregulated in cancerand proteolyze ... differences in cathepsin K, L, and Sactivity profiles between breast, lung, and cervical tissue and changes to these profiles as the cancer stageincreased. Ductal carcinoma breast cancers arise in theinner...